China Aoxing Pharmaceutical Corp. (OTCBB: CAXG) announced that on June 8, 2006 its subsidiary, Hebei Aoxing Pharmaceutical Group, received new product approvals from the State Food and Drug Administration, P.R. China. Both the Naloxone Hydrochloride itself and the Naloxone Hydrochloride injections in various specifications, have met applicable regulations detailed in the “Drug Administration Law of the People’s Republic of China” and obtained new drug registration approvals. The Company has also submitted the GMP-Qualification applications to the SFDA for its Naloxone Hydrochloride manufacturing facility and Naloxone Hydrochloride injection manufacturing facility.
